Bioregions deliver action plan blueprintWhile DG Research has delayed its update on the European Bioeconomy Strategy and Action Plan until next June, the Central and Eastern Bioregions presented a blueprint that proposes key actions aimed … more ➔
Germany lagging behind in stem cell resear...A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their … more ➔
Belgian Fund+ raises €125m for biotechsInvestors are once again flocking to back biotechs in Europe. Belgian Life Sciences fund Fund+ has raised €125m – a quarter more than initially anticipated. more ➔
ETH builds cyborg bacteriaPart microbe, part machine: cyborg bacteria developed at ETH Zurich could revolutionise the biotechnological production of molecules. The bacteria have been engineered to respond to light signals. more ➔
Nordic Nanovector in blood cancer pactNordic Nanovector is expanding its foothold in cancer-fighting ADCs. The Oslo-based biotech has inked a leukaemia pact with Wilex subsidiary Heidelberg Pharma. more ➔
EMA unveils trial dataTrial transparency has been a hotly debated topic over the last months, but now, the EMA is turning words into action. The agency will allow public access to clinical trial reports, starting now. more ➔
Dilaforette: Going public with a new nameNew name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future. more ➔
Ysios closes €126m BioFundSpanish start-ups, take heed: One of the biggest biotech funds in Southern Europe has just been closed by Ysios Capital. The Spanish venture firm raised €126.4m to be reinvested in European biotech, … more ➔
Merck drops MS collaboration with ApitopeApitope said it has regained global rights to its IL-10-bolstering vaccination ATX-MS-1467 for remitting-relapsing multiple sclerosis from Merck KGaA. A 2009 contract forsaw that Merck will … more ➔
EPO rules threaten biotech industryThe European Patent Offices decision to speed up examination of patent applications to 12 months without any transition period is set to ruin biotech SMEs financially and may send a blocking signal … more ➔
